Skip to main content

Table 1 Description of study population

From: Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Variablesa Co-infected
(n = 18)
HIV infections alone
(n = 18)
Demographic data
 Sex, female (%, CI) 11 (61.1) 11 (61.1)
 Age (median, IQR) 36.5 (33.8–41.5) 35.5 (30.8–45.2)
Clinical parameters
 CD4+ (median/IQR) 137 (35–197) 125 (50–182)
 WHO disease stage
  2 (n = 3) 2 (11.1 %) 1 (5.6 %)
  3 (n = 38) 15 (83.3 %) 13 (72.2 %)
  4 (n = 5) 1 (5.6 %) 4 (22.2 %)
 ARV combination
 d4T + 3TC + NVP (n = 8) 4 (22.2 %) 4 (22.2 %)
 d4T + 3TC + EFV (n = 11) 4 (22.2 %) 3 (16.7 %)
  CBV + NVP (n = 15) 5 (27.8 %) 6 (33.3 %)
  CBV + EFV (n = 12) 5 (27.8 %) 5 (27.8 %)
 Hepatitis virus markers
  HBeAg 10 (55.6 %)
  Anti-HBe 8 (44.4 %)
  Anti-HBc IgM 0 (0.0 %)
  1. aFor variable with n number of patients indicated, the percentages were calculated based on those values